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The role of renin-angiotensin-aldosterone system in the
progression of chronic kidney disease. The renin-angiotensin-
aldosterone system (RAAS) is a well known regulator of blood
pressure (BP) and determinant of target-organ damage. It con-
trols fluid and electrolyte balance through coordinated effects
on the heart, blood vessels, and Kidneys. Angiotensin II (AII)
is the main effector of the RAAS and exerts its vasoconstrictor
effect predominantly on the postglomerular arterioles, thereby
increasing the glomerular hydraulic pressure and the ultrafiltra-
tion of plasma proteins, effects that may contribute to the onset
and progression of chronic renal damage. AII may also directly
contribute to accelerate renal damage by sustaining cell growth,
inflammation, and fibrosis. Interventions that inhibit the activ-
ity of the RAAS are renoprotective and may slow or even halt
the progression of chronic nephropathies. ACE inhibitors and
angiotensin II receptor antagonists can be used in combina-
tion to maximize RAAS inhibition and more effectively reduce
proteinuria and GFR decline in diabetic and nondiabetic re-
nal disease. Recent evidence suggests that add-on therapy with
an aldosterone antagonist may further increase renoprotection,
but may also enhance the risk hyperkalemia.
Maximized RAAS inhibition, combined with intensified
blood pressure control (and metabolic control in diabetics)
and amelioration of dyslipidemia in a multimodal approach in-
cluding lifestyle modifications (Remission Clinic), may achieve
remission of proteinuria and renal function stabilization in a
substantial proportion of patients with proteinuric renal dis-
ease. Ongoing studies will tell whether novel drugs inhibiting
the RAAS, such as the renin inhibitors or the vasopeptidase
inhibitors, may offer additional benefits to those who do not
respond, or only partially respond, to this multimodal regimen.
Chronic kidney disease (CKD) is a major public health
problem, and preventing CKD and/or delaying progres-
sion of CKD patients to end-stage renal disease (ESRD)
is a major task for the nephrology community [1]. This
looks like an achievable target, in particular because of
the availability of renoprotective drugs that may inter-
fere with disease progression such as the inhibitors of
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the renin-angiotensin-aldosterone system (RAAS). Af-
ter the first inhibitor of angiotensin II (AII) system, the
angiotensin-converting enzyme (ACE) inhibitor capto-
pril, became available for clinical use in the early 1980s
[2], other drugs have become progressively available that
interfere with RAAS activity, such as AII-type 1 receptor
blockers (ARBs) and the aldosterone (Aldos) antago-
nists that inhibit AII and Aldos activity by competitively
antagonizing their binding to specific receptors [3]. In a
short future, novel agents that interfere with renin activity
(such as aliskiren) will also become available for clinical
use [4], which will further increase the armamentarium
of drugs that may interfere with the sequence of events,
eventually resulting in AII and Aldos production at dif-
ferent levels and that, used in combination, may achieve
an almost complete inhibition of the RAAS. In addition,
to identify the optimal regimens to maximize renopro-
tection, major efforts should be made in identifying and
treating all patients at risk, with the final aim to delay or
even prevent the onset and progression of chronic renal
disease and related complications [5].
ROLE OF THE RAAS IN THE DEVELOPMENT
AND PROGRESSION OF RENAL DISEASE
The RAAS is the best known regulator of blood
pressure (BP) and determinant of target-organ dam-
age from hypertension. It also controls fluid and elec-
trolyte balance through coordinated effects on the heart,
blood vessels, and kidneys. AII is the main effector of
the RAAS [6]. In the classic pathway of the RAAS,
renin is secreted from the juxtaglomerular apparatus
of the kidney and acts on the circulating precursor an-
giotensinogen to generate angiotensin I. Angiotensin I
has little effect on BP and is converted in the lungs
by ACE to AII. AII acts on the heart and the kidneys
by binding to the G protein–coupled receptors type 1
(AT1) and type 2 (AT2). The AT1 receptor mediates
the more deleterious effects of AII—that is, vasocon-
striction and cardiac and vessel hypertrophy. In addition
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to the conversion of angiotensin I to AII, ACE inacti-
vates the vasodilator peptide bradykinin [3]. Recently,
it has been discovered that the ACE type-2 (ACE2)
cleaves angiotensin I into the inactive angiotensin 1–9,
which is converted by ACE in the vasodilator and anti-
proliferative angiotensin 1–7, respectively [7, 8]. Al-
though ACE2 is known to be present in the human
kidney, there were no data on tissue distribution in re-
nal disease [7]. In a recent study, renal biopsies from
patients with diverse renal diseases including transplant
patients were studied. In control kidneys, ACE2 was
present in tubular and glomerular epithelium and in vas-
cular smooth muscle cells and the endothelium of inter-
lobular arteries [9]. In all renal diseases, neo-expression
of ACE2 was found in glomerular and peritubular cap-
illary endothelium. ACE inhibitor treatment did not
alter ACE2 expression [9]. In vivo, AII enhances the
vascular tone of both afferent and efferent glomeru-
lar arterioles and modulates intraglomerular capillary
pressure and glomerular filtration rate (GFR). AII ex-
erts its vasoconstrictor effect predominantly on the post-
glomerular arterioles, thereby increasing the glomerular
hydraulic pressure and the filtration fraction, and im-
pairs the size-selective function of the glomerular bar-
rier to macromolecules, such as plasma proteins [10].
Intracapillary hypertension and increased ultrafiltration
of plasma proteins may contribute to the onset and pro-
gression of chronic renal damage [11]. Nonhemodynamic
effect of angiotensin may also be important in renal dis-
ease progression [6]. These include increased production
of reactive oxygen species; upregulation of cytokines,
cell adhesion molecules, and profibrotic growth factors;
induction of transforming growth factor-b expression, in-
creased synthesis of extracellular matrix proteins; stim-
ulation of plasminogen activator inhibitor-1 production
by endothelial and vascular smooth muscle cells; and
macrophage activations and infiltrations [12]. Finally, AII
augments adrenal production of Aldos, a recently recog-
nized contributor to renal and cardiac injury [13]. Aldos
is the principal mineralocorticoid produced in the zona
glomerulosa layer of the adrenal cortex. It is also pro-
duced in endothelial and vascular smooth muscle cells
in the heart, blood vessels, and brain. Acting through
epithelial mineralocorticoid receptors in the kidney, car-
diovascular system, and other organs, Aldos plays a ma-
jor role in salt and water homeostasis and potassium
excretion, and mediates renal and vascular remodeling
[13]. In addition, to amplify some of the effects of AII,
Aldos may also directly contribute to endothelial dys-
function, as suggested by evidence that mineralocorti-
coid receptor blockade with spironolactone may increase
nitric oxide (NO) bioactivity and improve endothelial
dysfunction [14]. In recent experimental studies, nan-
otechniques showed that Aldos may also remodel human
endothelium in vitro by increasing the size and stiff-
ness of endothelial cells, which favors protein leakage
though intercellular gaps [15]. In addition to AII, other
angiotensin peptides may exert clinically relevant va-
soactive actions. Angiotensin 1-7 (A1-7), a heptapeptide
derived from angiotensin I and/or from AII, may an-
tagonize AII, especially in situations of an overactive
RAAS, such as during sodium restriction [16], an ef-
fect that results in renal vasodilation and increased na-
triuresis [17]. Also, digestion of the angiotensin I and
AII by angiotensinases-peptidases, aminopeptidases, car-
boxypeptidases, or endopeptidases result in different
peptide fragments with distinct functions from those of
AII. Angiotensin IV (the 3–8 peptide) binds selectively
the AT4 receptor and stimulates plasminogen activator
inhibitor-1 release [18]. The biologic significance of these
novel peptides is under investigation.
THE RELATIONSHIP BETWEEN RAAS
ACTIVITY, PROTEIN TRAFFIC, AND RENAL
DISEASE PROGRESSION
Experimental data from animal models have shown
that there are a wide variety of glomerular insults that
result in a common pathway of increased glomerular
hypertension, systemic hypertension, glomerular perme-
ability, and proteinuria. These diverse pathologies appear
to incite a vicious cycle of injury and inflammation, re-
sulting in a common pathophysiologic mechanism, in
which glomerular injury leads to proteinuria, intersti-
tial inflammation, and, ultimately, scarring [11]. The im-
portance of glomerular hypertension and hyperfiltration
in response to nephron loss was established by Brenner
et al [19]. After nephron loss, the remaining nephrons de-
velop glomerular capillary hypertension, and the single-
nephron GFR increases (hyperfiltration). These changes
are thought to be adaptive in that they help to initially
maintain the overall GFR. However, they have nega-
tive long-term effects and ultimately lead to renal insuf-
ficiency and ESRD. Proteinuria has been considered an
indicator of glomerular disease severity [20]. The pro-
posed effects of proteinuria on the kidney include in-
creased severity of glomerulosclerosis, tubulointerstitial
inflammation, and subsequent fibrosis, thereby contribut-
ing to progressive renal function loss. These facts have
permitted the establishment of a “proteinuria hypoth-
esis” that consists of three postulates: higher levels of
proteinuria predict adverse clinical outcomes; reduction
of proteinuria correlates with slowing of renal progres-
sion; and proteinuria is a surrogate end point and target
of clinical interventions [21]. Glomerular hypertension
in both diabetic and nondiabetic chronic nephropathies
leads to increased glomerular permeability and excessive
protein filtration. The protein ultrafiltrates are toxic to the
proximal tubules, resulting in tubular damage and finally
scarring [11]. The degree of proteinuria correlates with
Remuzzi et al: The RAAS in chronic kidney disease S-59
the magnitude of renal damage in experimental models,
and proteinuria reduction helps to preserve renal func-
tion [11]. Proteins in the urine are normally absorbed
by endocytosis in the proximal tubules. During periods
of heavy proteinuria, the filtered proteins accumulate in
lysosomes in the proximal tubular cells, causing cell dis-
ruption and injury [22, 23]. Proteins may also incite a toxic
response through stimulation of the expression of proin-
flammatory cytokines. Cultured proximal tubule cells that
are exposed to albumin, transferrin, or immunoglobu-
lin G produce increased amount of endothelin-1 (ET-1),
a powerful vasoconstrictor that also contributes to in-
flammation and fibrosis [24]. Exposure to albumin or
transferrin also increases the production of monocyte
chemotactic protein-1, which, in proximal tubule cell cul-
tures that maintain polarity, is preferentially excreted
into the basolateral compartment, suggesting a possible
mechanism for interstitial inflammatory infiltrates in vivo
[25]. These findings have been echoed in both immune
(Heyman nephritis) and non-immune (5/6 nephrectomy)
models of nephropathy, in which albumin, immunoglob-
ulins, and complement localize to proximal tubules that
later develop inflammatory infiltrates [26]. ET-1 expres-
sion is also increased, and the degree of expression cor-
relates with the rate of progression [27]. Treatment with
angiotensin-converting enzyme inhibitor (ACEI), which
decreases filtered proteins, also decreases the production
of these inflammatory cytokines and preserves renal func-
tion [28]. Lastly, the increased glomerular permeability
may result in excess ultrafiltration of some complement
proteins fractions that may be directly toxic to the prox-
imal tubules and incite injury. In a subtotal nephrectomy
model of renal insufficiency, C3 staining was associated
with the appearance of interstitial infiltrates. Treatment
with ACEI, which lowered proteinuria, also decreased
C3 staining [29].
Interventions that reduce glomerular capillary hyper-
tension, such as blockade of the RAAS [30, 31] or a
low-protein diet [19], slow the progression of chronic
nephropathy in experimental forms of nephropathy. In-
hibition of the RAAS, either through reducing the in
production of AII with ACEI or by blocking the action
of AII at the AT-R1 receptor level with ARBs, is par-
ticularly effective at preventing renal injury. The bene-
fit seen with these drugs is beyond that which would be
expected from their antihypertensive effects. Compared
with a non-ACEI regimen that achieved equivalent sys-
temic BP control, captopril better reduced glomerular
hypertension and renal injury [30]. In humans, prote-
inuria was the strongest predictor of renal disease pro-
gression: the higher baseline proteinuria, the faster GFR
decline [32]. It is now widely accepted that proteinuria
reduction is an appropriate therapeutic goal in CKD
with proteinuria [33]. In patients from the Ramipril Effi-
cacy In Nephropathy (REIN) long-term follow-up study,
who were at high risk of rapid progression to ESRD, 36
months of treatment with the ACEI ramipril reversed
the tendency of GFR to decline with time and prevented
progression to dialysis [34]. Recently, the Reduction of
Endpoints in Type 2 Diabetes Mellitus with the Angio-
tensin II Antagonist Losartan (RENAAL) study showed
that 6-month protein/creatinine ratio reduction predicts
renal and cardiovascular events in diabetic patients [35].
In summary, there is robust experimental evidence and a
number of hints from clinical observations that increased
protein ultrafiltration and excretion may contribute to the
pathogenesis of structural lesions and disease progression
in nephropathy [1].
THE CONTRIBUTION OF THE RAAS
ACTIVATION TO CHRONIC INFLAMMATION
AND TISSUE DAMAGE
CKD is characterized by a state of chronic inflamma-
tion that is associated with oxidative stress, endothelial
dysfunction, and vascular calcification and wasting [36].
The mechanism for this inflammatory status seems to be
related to a combination of diverse factors that cause an
altered immune balance [36]. Also, emerging evidence
suggests that AII is not only a vasoactive peptide, but
also a true cytokine that regulates cell growth, inflam-
mation, and fibrosis [12, 37]. Thus, some of AII-induced
effects are mediated by the production of a large array
of growth factors. AII in vivo increases tumor necrosis
factor-a production in the kidney and also upregulates
other proinflammatory mediators, including interleukin
6, monocyte chemotactic protein-1, and nuclear factor-
jB, which is associated with the presence of glomerular
and interstitial inflammatory cells in the kidney [37]. This
scenario opens the possibility that AII contributes to the
pathogenesis of renal diseases also by favoring the infil-
tration and activation of immunocompetent cells [38]. A
recent study has also revealed that angiotensin IV, via
AT4 receptors, activates nuclear factor-jB pathway and
increases proinflammatory genes [39]. There are some
data showing that some of the beneficial effects of the
RAAS blockade may be related to anti-inflammatory
properties of ACEI and ARBs [36]. In an experimental
study, Anderson et al reported an impaired cytokine-
induced nuclear factor-jB translocation from the cyto-
plasm to the nucleus in captopril preincubated mono-
cytes [40]. In a clinical study, Stevinkel et al found low
plasma levels of tumor necrosis factor-a and C-reative
protein (CRP) in ESRD patients treated with ACEI [41].
Also, in the SOLVD trial, those patients treated with an
ACEI reduced the risk of weight loss, which supports the
hypothesis of relationships among wasting, the RAAS,
and inflammation [42]. Although future clinical studies
are necessary to confirm the relevance of this hypothesis
for human disease conditions, this line of research could
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indicate new directions concerning RAAS blockade and
immunosuppression in renal diseases.
GENETIC DETERMINANTS OF THE RAAS
Several polymorphisms of genes coding for compo-
nents of the RAAS have been identified [43]. The most
important polymorphisms that have deserved numerous
studies were I/D polymorphism, a variant of the an-
giotensinogen gene, the M235T polymorphism, and the
variant A1166C polymorphism of the AII type-1 receptor
gene [44]. The exact mechanism by which the polymor-
phisms of the RAAS could influence the progression of
kidney disease is not clear. Several studies have suggested
a potential role for I/D polymorphism of the ACE gene
in the progression of renal diseases and in cardiovascular
complications of patients with CKD [45]. In the REIN
study, the DD genotype was associated with faster pro-
gression and better response to ACE inhibition therapy,
in particular in women [46]. Also, when angiotensinogen
and AII-type-1 receptor polymorphisms were analyzed,
most of the studies did not disclose any definitive relation
to renal disease progression [44]. However, in hyperten-
sive patients it has been suggested that the combination
of DD polymorphism type for ACE, TT for angiotensino-
gen, and AC/CC for AII-type-1 receptor gene, could con-
tribute in a synergistic way to organ damage [47]. The
relation between the degree of response to renoprotec-
tive therapies and polymorphism types has bought incon-
clusive results. A subanalysis of the REIN study showed
that only men with the DD type had a favorable response
to the treatment with ramipril [48]. In summary, to date,
results on the RAAS polymorphisms as determinants of
progression of CKD and of response to renoprotective
therapies are conflicting.
RENOPROTECTION THROUGH TREATMENTS
THAT INHIBIT THE RAAS
Drugs acting on the RAAS include agents that di-
rectly inhibit the synthesis and release of renin or AII
(renin and ACE inhibitors), drugs that antagonize the re-
ceptor effects of AII (ARBs), the aldosterone-receptor
antagonists, and a new class of combined ACEI and neu-
tral endopeptidase inhibitors, called the vasopeptidase
inhibitors (VPIs).
ANGIOTENSIN-CONVERTING ENZYME
INHIBITORS
Early studies of the mechanisms of conversion of an-
giotensin I to II, and of bradykinin hydrolysis, led to the
isolation (from snake venom) and synthesis of small pep-
tide inhibitors of ACE (kininase II) [2, 3]. ACEI proved
to be highly successful in the treatment of hypertension
and related target-organ damage, including left ventric-
ular hypertrophy, heart failure, and postmyocardial in-
farction left-ventricular remodeling, renal insufficiency,
and diabetes with proteinuria. After the introduction of
captopril for clinical use [2, 3], several ACEIs have been
developed, and many have been approved for the treat-
ment of hypertension, heart failure, diabetic nephropa-
thy, and/or left ventricular dysfunction. ACEIs differ in
their ability to penetrate and bind tissue sites for pro-
longed periods [3].
Diabetic nephropathy
Type 1 diabetes. The seminal study from Lewis et al
[49] found that in patients with overt nephropathy of type
1 diabetes, ACE inhibition with captopril induced a clear
reduction in proteinuria, as compared with treatment not
directly interfering in the RAAS. This effect was associ-
ated with a slower decline in GFR and a reduction of the
primary end point “doubling of serum-creatinine” of ap-
proximately 50%. The European Microalbuminuria Cap-
topril Study showed that in microalbuminuric patients
with type 1 diabetes, ACE inhibition decreases the risk to
develop overt nephropathy by approximately 75% [50],
which proves that ACE inhibition also has beneficial re-
nal effects at the earlier stage of incipient nephropathy.
Type 2 diabetes. Six small studies that included 352 pa-
tients uniformly found that ACE inhibition also reduces
proteinuria more effectively than conventional therapy
in overt nephropathy of type 2 diabetes [51]. The sub-
study in 3577 patients with diabetes (primarily type 2) of
the Heart Outcomes Prevention Evaluation trial showed
that, compared with placebo, treatment with the ACEI
ramipril resulted in a 24% reduction of the risk to develop
overt nephropathy in patients who were either normo-
or microalbuminuric [52]. More recently, The Bergamo
Nephrology Diabetic Complications Trial demonstrated
that the ACEI trandolapril, as compared with non-RAAS
inhibition antihypertensive therapies, halved the risk to
develop microalbuminuria in hypertensive patients with
type 2 diabetes and normoalbuminuria [53]. This effect
exceeded what could be expected on the basis of BP re-
duction and was non-enhanced by combined therapy with
the non-dihydropiridine calcium-channel blocker.
Nondiabetic nephropathy
In nondiabetic renal disease, there is a clear reno-
protective advantage of ACEI as compared with BP-
lowering therapies not interfering with the RAAS. The
REIN study included 352 patients with chronic nephro-
pathies of nondiabetic origin who were randomized to
treatment with ramipril or placebo on top of other anti-
hypertensive agents. The main finding was that ramipril
treatment resulted in a slower decline in GFR compared
with placebo, despite equivalent BP control [32]. A later
Remuzzi et al: The RAAS in chronic kidney disease S-61
analysis indicated that in a subset of patients on pro-
longed treatment with ramipril, the GFR stabilized and
then progressively increased [54]. Recently, the African
American Study of Kidney Disease and Hypertension
trial demonstrated that the renoprotective effect of ACE
inhibition is superior to that of conventional antihyper-
tensive regimens (including beta blockers and calcium-
channel blockers) in black patients [55], a population so
far considered to be poorly responsive to RAAS block-
ade.
ANGIOTENSIN RECEPTOR BLOCKERS
The ARBs are highly effective and well-tolerated anti-
hypertensive medications, and recent clinical trials have
shown that these agents have renoprotective effects be-
yond lowering BP. At present, there are several orally
active ARBs available. The ARBs are nonpeptide com-
pounds that specifically block the binding of AII to the
AT1 receptor [3]. They do not interact with AT2 receptors.
The block of feedback inhibition of renin release activates
the RAAS cascade and AII production. The AII gener-
ated may interact with AT2 receptors, an effect that may
result in vasodilatation and further BP reduction and,
according to some recent experimental evidence, may
result in inhibition of angiotensin and revascularization.
There are some structural differences among ARBs that
result in differences in pharmacokinetics and pharmaco-
dynamics [3]. However, differences in antihypertensive
potency and duration of action of the ARBs have been
inconsistently reported [56]. Recently, a possible benefi-
cial effect of telmisartan on metabolic syndrome has been
described. In fact, this ARB can function as a partial ago-
nist of peroxisome proliferator-activated receptor-c [57].
The clinical significance of these differences among mem-
bers of the class remains to be determined in outcome
trials.
Nephropathy associated with type 2 diabetes
Two important studies that included more than 1500
patients with type 2 diabetes and overt nephropathy, the
Irbesartan in Diabetic Nephropathy Trial [49] and the
RENAAL trial [35], found that ARB treatment, as com-
pared with conventional therapy, reduced the relative
risk of reaching the primary composite end point (dou-
bling of serum creatinine, ESRD, or death) by 20% and
16%, respectively. In addition, the Irbesartan in Diabetic
Nephropathy Trial showed a reduction of the risk to reach
the primary end point by 23% as compared with calcium-
channel blockade by amlodipine, the third treatment arm
in this study. Two other studies also showed the benefi-
cial effect of ARB at the stage of incipient nephropathy,
the Microalbuminuria Reduction with Valsartan study
[58] and the Irbesartan in Patients with Type 2 Diabetes
and Microalbuminuria study [59]. More recently, the DE-
TAIL study, a non-inferiority study that compared telmis-
artan and enalapril in 250 patients with type 2 diabetes
and microalbuminuria and macroalbuminuria [60], found
that telmisartan was not inferior to enalapril according to
predefined criteria. Data showed that at 5-year follow-up,
GFR had decreased by 17.5 mL/m/1.73 m2 with telmisar-
tan and by 15 mL/m/1.73m2 with enalapril.
SELECTIVE ALDOSTERONE-RECEPTOR
ANTAGONISTS
Several experimental studies have raised the possibil-
ity that Aldos in addition to AII may have a role in
progression of chronic renal disease [61, 62]. Chrysos-
tomou and Becker, in eight patients with various renal
diseases and persistent proteinuria (>1 g/d) and despite
treatment with enalapril for more than 12 months and
add-on therapy with spironolactone 25 mg per day,
decreased proteinuria by 54% as compared with pre-
treatment values [63]. This effect, however, was almost
entirely driven by the reduction in proteinuria observed
in the five patients with type 2 diabetes. Recently, a new
aldosterone-receptor blocker, eplerenone, has been de-
scribed, which differs from spironolactone by virtue of
higher selectivity for the Aldos receptor [64]. A double-
blind, prospective study evaluated eplerenone, enalapril,
and a combination of both agents in patients with type
2 diabetes mellitus, mild-to-moderate hypertension, and
proteinuria during a 24-week period [64]. Eplerenone de-
creased microalbuminuria independent of its antihyper-
tensive activity. Compared with enalapril, the renopro-
tective properties of eplerenone were significantly better,
however, and the reduction in albumin excretion with
combination therapy was significantly more effective
than monotherapy with either drug. Elevated potassium
levels were observed, and more patients were withdrawn
for hyperkalemia in the combination group. A subse-
quent follow-up study is being conducted to determine
if lower doses of eplerenone will maintain reductions in
albumin excretion without substantially increasing potas-
sium levels [64]. Combinations of low-dose eplerenone
with a low-dose thiazide-type diuretic appear to be op-
tions worth investigating, because the overall cardiovas-
cular benefit brought about by reducing BP would be
increased by the blockade of extrarenal aldosterone re-
ceptors provoked by eplerenone.
RENIN INHIBITORS
Blockade of the renin-angiotensinogen reaction is an
attractive therapeutic tool to synergize the renoprotec-
tion of RAAS inhibition, not only because this action is
the rate-limiting step in the RAAS, but also because the
active site of renin is highly selective for angiotensino-
gen [65]. In a recent study, the new molecule aliskiren
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(SPP100) showed that 150-mg daily doses were as effec-
tive as irbesartan 150 mg in lowering BP with a safety
and tolerability profile comparable with placebo [4]. The
co-administration of aliskiren with valsartan, in mildly
sodium-depleted normotensive individuals, had a syn-
ergistic effect on RAAS hormone levels [66]. Other
renin inhibitors are in earlier phases of investigation (i.e.,
enalkiren, zalkiren) [65].
VASOPEPTIDASE INHIBITORS
VPIs are novel antihypertensive medications that si-
multaneously inhibit ACE and neutral endopeptidase
(NEP) [67]. NEP catalyzes the hydrolysis of atrial natri-
uretic peptide (ANP), brain natriuretic peptide, and C-
type natriuretic peptide. Simultaneous inhibition of the
RAAS and NEP system by VPIs results in vasodilation,
natriuresis, and diuresis, and decreases peripheral vascu-
lar resistance and BP to a greater extent than ACE inhi-
bition alone. Thus, VPIs represent a new and attractive
therapeutic strategy for the treatment of cardiovascular
disease. In a recent experimental study in the remnant
kidney model, the administration of a VPI, AVE7688, at
the stage of overt nephropathy reduced proteinuria and
lessened renal damage better than enalapril at doses that
afforded a comparable BP control. Finding that AVE7688
corrected the imbalanced ratio between the vasoconstric-
tor ET-1 and the vasodilators NO and ANP, may explain
the superior renoprotection of vasopeptidase over ACE
inhibitors [68]. The risk/benefit profile of VPI therapy on
top of the best renoprotective therapy, however, is still a
matter of investigation [69]. At present, several VPIs are
in various stages of development. Omapatrilat is one that
has undergone the most extensive clinical development,
in particular in heart failure. However, the high incidence
of angioedema compared with enalapril—as reported in
the Omapatrilat Cardiovascular Treatment Assessment
Versus Enalapril trial—might limit its use [70].
MULTIPLE DRUG TREATMENT: PRACTICAL
GUIDELINES TO ACHIEVE REMISSION AND
REGRESSION
Intensified BP and metabolic control in diabetics, re-
duction of proteinuria, block of the RAAS, and lifestyle
changes (smoking cessation, weight reduction) may
achieve chronic renal disease remission, with GFR sta-
bilization and proteinuria reduction to subclinical ranges
in a consistent proportion of patients with diabetic or
nondiabetic chronic nephropathies [5]. Targets of treat-
ment are BP less than 120/80 mm Hg, proteinuria less
than 0.3 g/24 h, low-density lipoprotein (LDL) less than
100 mg/dL, LDL plus very LDL less than 130 mg/dL,
and hemoglobin-A1c less than 7.5% (in diabetes) [5].
Maximized inhibition of the RAAS by combined treat-
ment with ACEI and ARB is the key component of
this multidrug regimen. In this sense, the Combination
Treatment of Angiotensin Receptor Blocker and An-
giotensin Converting Enzyme Inhibitor in Non-diabetic
Renal Disease study showed that in patients with non-
diabetic nephropathies, dual RAAS blockade with tran-
dolapril and losartan provided better renoprotection than
either drug alone [71]. In the same way, the Candesar-
tan and Lisinopril Microalbuminuria study found that
in type 2 diabetic patients with incipient nephropathy,
lisinopril and candesartan achieved more reduction in
albuminuria than each treatment alone; however, this
was an effect that was also associated with more effec-
tive BP reduction [72]. Further blockade of the system
by add-on therapy with an Aldos antagonist could pos-
sibly offer additional renoprotection but may have the
drawback of severe hyperkalemia [13]. In experimental
animals, add-on statin therapy, in addition to ameliorate
lipid profile, may achieve further proteinuria reduction
[73]. Whether 3-hydroxy-3-methylglutaryl coenzyme A
inhibition added to maximized RAAS inhibition may
achieve further renoprotecion is a matter of investiga-
tion.
THE RAAS BLOCKADE IN CHRONIC
ALLOGRAFT REJECTION
In Western countries, allograft rejection is becoming
the third cause of ESRD. The functional and structural
changes of chronic renal allograft nephropathy (CAN)
show similarities with those observed in other forms of
chronic progressive renal disease, in which inadequate
functioning nephron mass has been considered the key
event [74]. In a meta-analysis of 100 controlled and un-
controlled studies involving 2494 patients, Kasiske et al
found that ACEIs were renoprotective in patients with
CAN [75]. Data from retrospective studies show that
early ACEI or ARB are well tolerated in renal trans-
plant patients, and may even shorten the time of graft
function recovery [76]. The risk/benefit profile of RAAS
inhibition early posttransplant, however, remains to be
established, along with the possibility that this approach
may achieve effect in CAN prevention.
THE ECONOMIC COST OF THE RAAS
BLOCKADE
Direct and indirect costs of ERDS are increasing ex-
ponentially worldwide. The economic impact of delayed
progression to ESRD would be enormous, as docu-
mented by findings that a 30% reduction in the rate of
GFR decline would translate into savings of more than
$60 billion in the United States by the year 2010 [77].
Clearly, there is a pressing need for effective identifi-
cation and early treatment of patients at risk, including
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type 2 diabetics with nephropathy, who currently rep-
resent the largest part of patients at risk of ESRD [78,
79]. Despite the cost of screening and early treatment,
studies show that early intervention, in particular with
RAAS inhibitors, is cost-effective. Thus, the economic
evaluation of the RENAAL study showed that losartan
and conventional therapy compared with placebo and
conventional therapy significantly reduced the number
of days with ESRD by 33.6 per patient over 3.5 years.
This reduction in ESRD days resulted in a decrease in
cost associated with ESRD of US $5144 per patient. Af-
ter accounting for the cost of losartan, the reduction in
ESRD days resulted in a net savings of US $3522 per
patient over 3.5 years [80]. In a cost-effectiveness analy-
sis from the data of REIN Study, patient-year of chronic
(long-term) dialysis avoided quantification, and statutory
health insurance expenses were analyzed. Results from
this evaluation show that ramipril offers enormous sav-
ings from the perspective of the statutory health insur-
ance provider (third-party payer) and per patient-year of
chronic (long-term) dialysis after 1, 2, and 3 years of treat-
ment [81]. Also, an analysis performed from the REIN
study estimated the direct medical costs of conservative
and renal replacement therapy from a payer’s perspective
[82]. The time to ESRD was predicted by two different
models based on the rate of GFR decline (DeltaGFR)
and incidence of ESRD (events) measured in 117 and
166 patients, respectively. Both in the DeltaGFR-based
or events-based models, ramipril delayed progression to
ESRD and prolonged patient survival by 1.5 to 2.2 and
1.2 to 1.4 years, respectively, and saved US $16,605 to
$23,894 during the patient’s lifetime and US $2422 to
$4203 yearly direct costs per patient. Thus, early interven-
tion is feasible and cost-effective. Now, the key problem
is allowing access to essential medicine for all patients
in need, in particular those in the poorest or developing
countries [83].
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